The rapid advances in imaging technologies are a challenge for nuclear medi
cine physicians, radiologists, and clinicians who must integrate these tech
nologies for optimal patient care and outcome at minimal cost. Multiple ind
ications for functional imaging using F-18-fluorodeoxyglucose (FDG) are now
well accepted in the field of oncology, including differentiation of benig
n from malignant lesions, staging malignant lesions, detection of malignant
recurrence, and monitoring therapy. The use of FDG imaging was first shown
using dedicated positron emission tomography (PET) with multiple full ring
s of bismuth germanate detectors. Most manufacturers now have available hyb
rid gamma cameras capable of imaging conventional single-photon emitters, a
s well as positron emitters such as FDG, This new technology was developed
to make FDG imaging more widely accessible, first using single photon emiss
ion computed tomography (SPECT) with high-energy collimators. and then usin
g dualhead coincidence (DHC) detection with multihead gamma cameras that im
proved spatial resolution. Most hybrid gamma cameras are now equipped with
thicker Nal(Tl) crystals to improve sensitivity. Technical developments are
still evolving with correction for attenuation and new iterative reconstru
ction algorithms to improve the quality of the images. Users need to be fam
iliar with the rapid developments of the technology as well as its limitati
ons. Currently, one model of hybrid gamma camera is equipped with an integr
ated x-ray transmission system for attenuation correction, anatomic mapping
, and image fusion, This powerful tool has promising clinical applications
including intensity-modulated radiation therapy. Copyright (C) 2000 by W.B.
Saunders Company.